Amylyx Pharmaceuticals, Inc.
corporate_fare Company Profile
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for AMLX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for AMLX spans 10-Q, 8-K, 424B5, DEF 14A.
Recent high-impact activity:
- Amylyx Q3 Loss Widens to $45.5M as Avexitide Launch Prep Drives Spend; $768.1M Cash
- Amylyx Secures Long-Term Avexitide Manufacturing with Bachem and Polypeptide
- Amylyx Formalizes $500M Upsized Offering: $471.7M Net Proceeds, Closing August 21
- Amylyx Prices Upsized $500M Offering at $35.50 After Avexitide Win
- Amylyx Upsizes Offering to $500M After Avexitide Win, Pricing at $35.50
Financial Snapshot
Short Interest & Short Volume
10.47 days to coverFINRA reported short interest of 12,823,384 shares in AMLX as of the October 30, 2026 settlement, a 3.2% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 54.3% of AMLX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for AMLX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-20.
Offering Upsized to $500M · Dilution of ~12.7%
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →